Compile Data Set for Download or QSAR
Report error Found 145 Enz. Inhib. hit(s) with all data for entry = 11474
TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465303(US10793564, Compound 92 | US11560376, Compound 92 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465304(US10793564, Compound 93 | US11560376, Compound 93 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465305(US10793564, Compound 94 | US11560376, Compound 94 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465316(US10793564, Compound 105 | US11560376, Compound 10...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465317(US10793564, Compound 106 | US11560376, Compound 10...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465311(US10793564, Compound 100 | US11560376, Compound 10...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465291(US10793564, Compound 80 | US11560376, Compound 80 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM566530(US11560376, Compound 81 | US11419869, Compound 81 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465293(US10793564, Compound 82 | US11560376, Compound 82 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465294(US10793564, Compound 83 | US11560376, Compound 83 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465287(US10793564, Compound 76 | US11560376, Compound 76 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465288(US10793564, Compound 77 | US11560376, Compound 77 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465289(US10793564, Compound 78 | US11560376, Compound 78 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465290(US10793564, Compound 79 | US11560376, Compound 79 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465300(US10793564, Compound 89 | US11560376, Compound 89 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465301(US10793564, Compound 90 | US11560376, Compound 90 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465302(US10793564, Compound 91 | US11560376, Compound 91 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465339(US10793564, Compound 129 | US11560376, Compound 12...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465340(US10793564, Compound 130 | US11560376, Compound 13...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465347(US10793564, Compound 137 | US11560376, Compound 13...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465348(US10793564, Compound 138 | US11560376, Compound 13...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465349(US10793564, Compound 139 | US11560376, Compound 13...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465221(US10793564, Compound 10 | US11560376, Compound 10 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465350(US10793564, Compound 140 | US11560376, Compound 14...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465222(US10793564, Compound 11 | US11560376, Compound 11 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465216(US10793564, Compound 55 | US10793564, Compound 5 |...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465346(US10793564, Compound 136 | US11560376, Compound 13...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465218(US10793564, Compound 7 | US11560376, Compound 7 | ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465324(US10793564, Compound 114 | US11560376, Compound 11...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465320(US10793564, Compound 109 | US11560376, Compound 10...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465321(US10793564, Compound 110 | US11560376, Compound 11...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465322(US10793564, Compound 111 | US11560376, Compound 11...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465333(US10793564, Compound 123 | US11560376, Compound 12...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465334(US10793564, Compound 124 | US11560376, Compound 12...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465327(US10793564, Compound 117 | US11560376, Compound 11...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465243(US10793564, Compound 32 | US11560376, Compound 32 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465244(US10793564, Compound 33 | US11560376, Compound 33 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465246(US10793564, Compound 35 | US11560376, Compound 35 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465239(US10793564, Compound 28 | US11560376, Compound 28 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465240(US10793564, Compound 29 | US11560376, Compound 29 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465241(US10793564, Compound 30 | US11560376, Compound 30 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465242(US10793564, Compound 31 | US11560376, Compound 31 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465251(US10793564, Compound 40 | US11560376, Compound 40 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465252(US10793564, Compound 41 | US11560376, Compound 41 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465253(US10793564, Compound 42 | US11560376, Compound 42 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465254(US10793564, Compound 43 | US11560376, Compound 43 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465249(US10793564, Compound 38 | US11560376, Compound 38 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465250(US10793564, Compound 39 | US11560376, Compound 39 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465355(US10793564, Compound 145 | (S)-4-((2-(dimethylamin...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465222(US10793564, Compound 11 | US11560376, Compound 11 ...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

Displayed 1 to 50 (of 145 total ) | Next | Last >>
Jump to: